Panelists discuss, current operational strategies and best practices for the implementation of bispecific antibody therapies, strategies for managing adverse effects associated with bispecific antibody therapies in multiple myeloma, opportunities for delivering bispecific antibody therapies for multiple myeloma in community healthcare settings, addressing challenges related to initial implementation, patient monitoring, and coordination with tertiary care centers.